CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (Unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Revenues:
Revenues	$ 1,933.7	$ 1,608.0	$ 3,645.5	$ 3,119.5
Expenses:
Research and development	1,048.3	529.3	1,690.1	1,027.9
Selling, general, and administrative	417.3	364.8	828.1	695.6
Total expenses	1,618.1	985.8	2,849.9	1,930.1
Income from operations	315.6	622.2	795.6	1,189.4
Other income (expense):
Other (expense) income, net	(82.9)	40.8	(9.1)	65.4
Interest expense	(8.0)	(6.9)	(15.7)	(13.3)
Total other income (expense)	(90.9)	33.9	(24.8)	52.1
Income before income taxes	224.7	656.1	770.8	1,241.5
Income tax expense	(31.6)	(104.7)	(116.6)	(212.1)
Net income	$ 193.1	$ 551.4	$ 654.2	$ 1,029.4
Net income per share - basic (in dollars per share)	$ 1.77	$ 5.12	$ 6.00	$ 9.56
Net income per share - diluted (in dollars per share)	$ 1.68	$ 4.82	$ 5.69	$ 8.97
Weighted average shares outstanding - basic (in shares)	109.2	107.8	109.1	107.7
Weighted average shares - diluted (in shares)	114.6	114.5	115.0	114.7
Statements of Comprehensive Income
Net income	$ 193.1	$ 551.4	$ 654.2	$ 1,029.4
Other comprehensive income (loss), net of tax:
Unrealized gain (loss) on debt securities	14.4	3.4	30.5	(7.7)
Unrealized (loss) gain on cash flow hedges	(1.4)		(2.4)
Unrealized (loss) gain on cash flow hedges		0.6		2.0
Comprehensive income	206.1	555.4	682.3	1,023.7
Product
Revenues:
Revenues	1,205.3	996.4	2,309.7	1,984.3
Expenses:
Cost of goods sold	67.0	36.0	137.9	105.2
Collaboration and contract manufacturing
Expenses:
Cost of goods sold	85.5	55.7	193.8	101.4
Sanofi | Product and service, other
Revenues:
Revenues	349.1	237.8	595.5	427.2
Bayer | Product and service, other
Revenues:
Revenues	289.0	262.9	565.2	510.8
Other | Product and service, other
Revenues:
Revenues	$ 90.3	$ 110.9	$ 175.1	$ 197.2